Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab

被引：0
作者：
Bernhard Scheiner
Matthias Pinter
机构：
[1] Medical University of Vienna,Division of Gastroenterology and Hepatology, Department of Internal Medicine III
[2] Medical University of Vienna,Liver Cancer (HCC) Study Group Vienna
来源：
memo - Magazine of European Medical Oncology | 2022年 / 15卷
关键词：
Immune-related hepatitis; Lichen ruber; Immunotherapy; Liver cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
We present a case of a male patient with advanced hepatocellular carcinoma who developed hepatic and dermatological immune-related adverse events during treatment with the immune checkpoint inhibitor nivolumab. We discuss relevant aspects regarding the management of immune-related hepatic adverse events, including the incidence and onset of the event, the requirement for immune-modulating medication, resuming of immunotherapy, and the association between the occurrence of immune-related adverse events and the outcome.
引用
收藏
页码：58 / 61
页数：3
相关论文
共 41 条
  • [1] Bruix J(2021)Systemic treatment of hepatocellular carcinoma: an EASL position paper J Hepatol 7 113-123
  • [2] Chan SL(2021)The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review JAMA Oncol 382 1894-1905
  • [3] Galle PR(2020)Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma N Engl J Med 72 320-341
  • [4] Pinter M(2020)Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma J Hepatol 28 iv119-iv142
  • [5] Jain RK(2017)Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 13 473-486
  • [6] Duda DG(2016)Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination Nat Rev Clin Oncol 57 36-49
  • [7] Finn RS(2017)Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions Cancer Treat Rev 70 e89-e1540
  • [8] Qin S(2019)PS-139-Liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy J Hepatol 25 e1532-378
  • [9] Ikeda M(2020)Nivolumab in advanced hepatocellular carcinoma: safety profile and select treatment-related adverse events from the checkmate 040 study Oncologist 4 374-2737
  • [10] Sangro B(2021)Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis J Am Acad Dermatol 37 2730-1956
12345